Photo of { Cuixia Tian, MD}

Cuixia Tian, MD


  • Director, MDA Clinic and PPMD Certified DMD Clinic, Division of Neurology
  • Neuromuscular Disease Specialist, Division of Neurology
  • Professor, UC Department of Pediatrics
My team and I are focused on families' concerns and work together to provide the best care possible to our patients.
Cuixia Tian, MD

About

Biography

I'm a board-certified child neurologist who specializes in neuromuscular diseases. I am co-director of the multidisciplinary comprehensive neuromuscular care program and serve as the program's neurology lead. I'm also the clinical director of the Parent Project Muscular Dystrophy (PPMD) Certified Duchenne Muscular Dystrophy (DMD) Clinic and clinical director of the Muscular Dystrophy Association (MDA) Care Center.

My mom was a devoted elementary teacher, loved by many of her students. Her love for children inspired me, and I became a pediatrician. I am honored to be recognized by Cincinnati Magazine’s Top Doctors in Pediatric Neurology (2023).

I'm passionate about caring for children and young adults with chronic neuromuscular disease. I love meeting families and listening to parents advocating for their children. My team and I are focused on families' concerns and work together to provide the best care possible to our patients.

As a clinical researcher, I actively lead and collaborate on multiple clinical trials and research studies in pediatric neuromuscular diseases to develop advanced therapies and improve clinical care for our patients.

When I'm not at work, I love music and the arts. I also enjoy gardening and playing tennis.

MD: Medical Center of Fudan University, Shanghai, China, 1993

Residency: Cincinnati Children’s Hospital Medical Center

Myology Institute Clinical Myology Training: Paris, France, 2014

Wellstone Myology Training: Ohio State University, Columbus, OH, 2013

World Muscle Society Satellite Training: Asilomar, CA, 2013

Additional Languages

Chinese

Insurance Information

Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.

View Insurance Information

Publications

Managing growth and puberty concerns in individuals with Duchenne muscular dystrophy: Updated guidance and future directions. Rutter, MM; Crane, JL; Babalola, F; Benjamin, RW; Lam, C; Mcadam, L; Nicolau, S; Sbrocchi, AM; Scavina, M; Sorbara, J; Weber, DR; Wong, SC; Zito, I; Wood, CL. Journal of Neuromuscular Diseases. 2026; 22143602261486896.

2.64eP QTc prolongation in an individual with Duchenne muscular dystrophy treated with givinostat and lessons for clinicians. Tian, C; Zygmunt, A; Reebals, L; Wade, C; Horn, P; Mcanally, M; Mantell, B; Villa, C. Neuromuscular Disorders. 2026; 67:106823.

2.36eP Assessing side effects of thrombocytopenia and hypertriglyceridemia for individuals with Duchenne muscular dystrophy treated with givinostat. Horn, P; Reebals, L; Zygmunt, A; Bramer, A; Mcanally, M; Wade, C; Tian, C. Neuromuscular Disorders. 2026; 67:106796.

2.17eP Fatal fat embolism syndrome without recognized fracture in patients with Duchenne muscular dystrophy: two case reports. Wade, C; Villa, C; Goldstein, LB; Tian, C; Zygmunt, A; Rice, K; Bagwell, L; Mcgovern, E; Toupin, DN. Neuromuscular Disorders. 2026; 67:106741.

2.13eP Tolerability of givinostat in combination with exon-skipping therapy in individuals with Duchenne muscular dystrophy. Wade, C; Bramer, A; Horn, P; Zygmunt, A; Reebals, L; Mcanally, M; Tian, C. Neuromuscular Disorders. 2026; 67:106737.

07O An interdisciplinary evaluation of the impact of GLP-1 receptor agonists in individuals with Duchenne muscular dystrophy. Deng, L; Greiner, E; Tian, C; Nasomyont, N; Villa, C; Sawnani, H; Rutter, M. Neuromuscular Disorders. 2026; 67:106940.

2.57P Real-world experience of safety and tolerability in 89 individuals with Duchenne muscular dystrophy initiating givinostat treatment; a retrospective review. Reebals, L; Bramer, A; Horn, P; Zygmunt, A; Mcanally, M; Tian, C. Neuromuscular Disorders. 2026; 67:106830.

Adrenal insufficiency in individuals with Duchenne muscular dystrophy treated with glucocorticoids: Insights from the past, current challenges, and future directions. Weber, DR; Ahmet, A; Kinnett, K; Lautatzis, M-E; Mcmillan, HJ; Apkon, S; Bansal, S; Benjamin, RW; Clemens, PR; Crane, JL; Veerapandiyan, A; Wong, SC; Ward, LM; Sbrocchi, AM. Journal of Neuromuscular Diseases. 2026; 22143602261485046.

Siblings With Duchenne Muscular Dystrophy: Exploring Diagnosis Age and Disease Progression in a Genetic Therapy‐Naïve Cohort. Brahmamdam, V; Tian, C; Armstrong, N; Pilipenko, V; Martin, LJ; Zygmunt, A; Rybalsky, I; Reebals, L; Nagaraj, CB. Annals of the Child Neurology Society. 2026.

Deramiocel heart-derived cellular therapy in advanced Duchenne muscular dystrophy (HOPE-3): a phase 3, randomised, double-blind, placebo-controlled trial. Mcdonald, CM; Villa, C; Soslow, JH; Maharry, K; Hogan, N; Binks, M; Berth, KC; Elliott, KA; Taylor, M; Hor, KN; Mercuri, E; Awadalla, MS; Marbán, L; Marbán, E. The Lancet. 2026; 408(10556):721-733.

Patient Ratings and Comments

All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent experience management company, Qualtrics. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey

Loading ...
Loading ...